Table 3.
Subgroup Analyses of progress-free survival prognosis of NSCLC EGFR-mutated patients
| Factor | N | HR (95% CI) | P value |
|---|---|---|---|
| Gender | |||
| Female | 70 | 1.06 (0.54, 2.09) | 0.8586 |
| Male | 47 | 2.17 (0.69, 6.85) 0.1862 | 0.1862 |
| Brain metastasis | |||
| No | 62 | 0.82 (0.36, 1.86) | 0.6417 |
| Yes | 55 | 2.28 (1.01, 5.14) | 0.0469 |
| EGFR mutation | |||
| 19del | 49 | 1.28 (0.56, 2.97) | 0.5588 |
| 21-L858R | 60 | 0.92 (0.40, 2.11) | 0.8510 |
| Other | 8 | 1.41 (0.08, 23.57) | 0.8092 |
| TP53 mutation | |||
| Yes | 42 | 2.90 (0.62, 13.66) | 0.1777 |
| No | 75 | 1.00 (0.53, 1.89) | 0.9985 |
| Initial treatment | |||
| 1 generation TKI | 65 | 1.07 (0.50, 2.28) | 0.8580 |
| 2 generation TKI | 14 | 1.89 (0.33, 10.74) | 0.4732 |
| 3 generation TKI | 31 | 2.07 (0.62, 6.89) | 0.2335 |
| 1 generation TKI + Anlotinib | 7 | 3.46 (0.22, 55.78) | 0.3809 |
Abbreviations: CI confidence interval, HR hazard ratio, EGFR epidermal growth receptor, 19del exon 19 deletion, 21-L858R exon 21 Leu858Arg, TKI tyrosine kinase inhibitor. bold was considered significant